Cellular and Molecular Regulation of CD8+ T cell memory

CD8 T 细胞记忆的细胞和分子调控

基本信息

项目摘要

DESCRIPTION (provided by applicant): CD8+ memory T cells (CTL) can confer lifelong protection from a wide variety of viral and bacterial pathogens, and can mediate the eradication of tumors. Conversely, CTL cause pathogenic autoimmunity and undesirable rejection of tissue grafts when not properly regulated. A mechanistic understanding of how memory CTL are established and maintained would allow for new approaches to inducing antigen-specific activation versus tolerance according to a patient's clinical need. The provision of "help" by CD4+ T lymphocytes (TH) to CTL represents an important control point in this pathway as it involves the transmission of signals that are critical for their functional activation and development into memory cells. Our ongoing studies have yielded key insights in this pathway by showing TH acts early during CTL priming to establish a program of development which allows them to undergo secondary expansion and avoid of TRAIL-mediated activation-induced cell death (AICD) upon reencounter with antigen. More recently, we have shown that the transcriptional regulator Nab2 controls the induction of TRAIL in "helped" versus "helpless" CTL. Furthermore, we have been able to prove an entirely new model of T help for CTL that reconciles differences implicit in the two previous models by showing that CD40-mediated APC activation by TH endows CTL with the capacity to produce their own autocrine IL-2. Taken together, the observations lay the foundation for a new exploration of the mechanisms underlying the generation of CTL memory and offer new possibilities for their strategic manipulation. The goal of this research is to complete our understanding of the cellular and molecular mechanism through which TH is transmitted to CTL. Outstanding questions in this regard include 1) identification of the signals provided by TH-activated APC to CTL that constitute the "help" message leading to memory functionality, 2) understanding the conditions under which autocrine versus paracrine (i.e. CD4-produced) IL-2 is involved in CTL responses, and 3) achieving a mechanistic understanding of how certain immunogens generate TH-independent memory CTL. We will examine each of these areas through the functional, phenotypic, and molecular analysis of primary CTL using in vivo models of infection and immunity. Our central hypothesis in these studies is that TH-activated APC transmit specific and inducible signals via the CD70-CD27 pathway to generate memory CTL, that paracrine (TH-produced) IL-2 can be important for responses against poorly immunogenic antigens, and that TH-independent CTL are produced by direct and indirect activation of APC by inflammatory stimuli, leading to transmission of the same distal signals as those achieved by TH through CD40-activation. Successful completion of this project will place the generation of memory CTL on a firm experimental and theoretical foundation and allow a greater potential for it's manipulation in health and disease.
描述(由申请人提供):CD 8+记忆T细胞(CTL)可以提供终身保护,免受各种病毒和细菌病原体的侵害,并可以介导肿瘤的根除。相反,当不适当调节时,CTL引起致病性自身免疫和组织移植物的不期望的排斥。对记忆性CTL如何建立和维持的机制性理解将允许根据患者的临床需要诱导抗原特异性激活与耐受的新方法。由CD 4 + T淋巴细胞(TH)向CTL提供“帮助”代表了该途径中的重要控制点,因为它涉及对其功能激活和发育成记忆细胞至关重要的信号的传递。我们正在进行的研究已经在这一途径中产生了关键的见解,通过显示TH在CTL引发过程中的早期作用,以建立一个发展计划,该计划允许它们进行二次扩增,并避免再次遇到抗原时TRAIL介导的活化诱导的细胞死亡(AICD)。最近,我们已经表明,转录调节因子Nab 2控制诱导的TRAIL在“帮助”与“无助”的CTL。此外,我们已经能够证明一个全新的模型的T细胞帮助CTL,调和在两个先前的模型中隐含的差异,显示CD 40介导的APC激活TH赋予CTL的能力,产生自己的自分泌IL-2。综上所述,这些观察结果为新探索CTL记忆产生的机制奠定了基础,并为其策略操纵提供了新的可能性。本研究的目的是完成我们对TH传递给CTL的细胞和分子机制的理解。这方面的突出问题包括1)鉴定TH激活的APC向CTL提供的信号,其构成导致记忆功能的“帮助”信息,2)理解自分泌与旁分泌(即CD 4产生的)IL-2参与CTL应答的条件,和3)实现某些免疫原如何产生TH非依赖性记忆CTL的机制理解。我们将通过使用感染和免疫的体内模型对初级CTL进行功能、表型和分子分析来检查这些区域中的每一个。我们在这些研究中的中心假设是TH激活的APC通过CD 70-CD 27通路传递特异性和诱导性信号,产生记忆CTL,(TH-产生的)IL-2对于针对免疫原性差的抗原的应答可能是重要的,并且TH-非依赖性CTL是通过炎症刺激直接和间接激活APC产生的,导致与TH通过CD 40活化实现的那些相同的远端信号的传输。该项目的成功完成将为记忆CTL的产生奠定坚实的实验和理论基础,并为健康和疾病的操纵提供更大的潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephen Philip Schoenberger其他文献

Stephen Philip Schoenberger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephen Philip Schoenberger', 18)}}的其他基金

Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer
不可逆电穿孔 (IRE) 联合 CD40 激动作为胰腺癌原位疫苗治疗
  • 批准号:
    10718057
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
Local control of anti-tumor/anti-self reactivity in low-affinity ACT
低亲和力 ACT 中抗肿瘤/抗自身反应性的局部控制
  • 批准号:
    8990833
  • 财政年份:
    2014
  • 资助金额:
    $ 44.25万
  • 项目类别:
Local control of anti-tumor/anti-self reactivity in low-affinity ACT
低亲和力 ACT 中抗肿瘤/抗自身反应性的局部控制
  • 批准号:
    8810185
  • 财政年份:
    2014
  • 资助金额:
    $ 44.25万
  • 项目类别:
Cellular and Molecular Regulation of CD8+ T cell memory
CD8 T 细胞记忆的细胞和分子调控
  • 批准号:
    8563544
  • 财政年份:
    2013
  • 资助金额:
    $ 44.25万
  • 项目类别:
Cellular and Molecular Regulation of CD8+ T cell memory
CD8 T 细胞记忆的细胞和分子调控
  • 批准号:
    9047234
  • 财政年份:
    2013
  • 资助金额:
    $ 44.25万
  • 项目类别:
2009 Antigen Cross Presentation Gordon-sponsored Meeting
2009 年戈登赞助的抗原交叉展示会议
  • 批准号:
    7671922
  • 财政年份:
    2009
  • 资助金额:
    $ 44.25万
  • 项目类别:
La Jolla Immunology Conference
拉霍亚免疫学会议
  • 批准号:
    8322085
  • 财政年份:
    2008
  • 资助金额:
    $ 44.25万
  • 项目类别:
La Jolla Immunology Conference
拉霍亚免疫学会议
  • 批准号:
    8597885
  • 财政年份:
    2008
  • 资助金额:
    $ 44.25万
  • 项目类别:
La Jolla Immunology Conference
拉霍亚免疫学会议
  • 批准号:
    8088081
  • 财政年份:
    2008
  • 资助金额:
    $ 44.25万
  • 项目类别:
Programming of CD8+ T Cell Tolerance by B Cell APC
B 细胞 APC 对 CD8 T 细胞耐受性进行编程
  • 批准号:
    7428877
  • 财政年份:
    2007
  • 资助金额:
    $ 44.25万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了